title: [Marihuana and cannobinoids as medicaments].
abstract: Biological activity of cannabinoids is caused by binding to two cannabinoid receptors CB1 and CB2. Psychoactive is not only tetrahydrocannabinol (THC) but also: cannabidiol, cannabigerol or cannabichromen. Formerly, the usefulness of hemp was assessed in the relation to temporary appeasement of the symptoms of some ailments as nausea or vomiting. Present discoveries indicates that cannabis-based drugs has shown ability to alleviate of autoimmunological disorders such as: Multiple sclerosis (MS), Rheumatoid arthritis (RA) or inflammatory bowel disease. Another studies indicates that cannabinoids play role in treatment of neurological disorders like Alzheimer disease or Amyotrophic lateral sclerosis (ALS) or even can reduce spreading of tumor cells. Cannabinoids stand out high safety profile considering acute toxicity, it is low possibility of deadly overdosing and side-effects are comprise in range of tolerated side-effects of other medications. In some countries marinol and nabilone are used as anti vomiting and nausea drug. First cannabis-based drug containg naturally occurring cannabinoids is Sativex. Sativex is delivered in an mucosal spray for patients suffering from spasticity in MS, pain relevant with cancer and neuropathic pain of various origin. Despite the relatively low acute toxicity of cannabinoids they should be avoid in patients with psychotic disorders, pregnant or breastfeeding woman. Cannabinoids prolong a time of reaction and decrease power of concentration that's why driving any vehicles is forbidden. Cannabis side-effects varies and depend from several factors like administrated dose, rout of administration and present state of mind. After sudden break from long-lasting use, withdrawal symptoms can appear, although they entirely disappear after a week or two.
authors: Krakowska Wyzsza Szkoła Promocji Zdrowia, Kraków.
authors: Marek
authors: M
authors: Tkaczyk
authors: Ewa
authors: E
authors: Florek
authors: Wojciech
authors: W
authors: Piekoszewski
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002185:Cannabidiol; D002186:Cannabinoids / Q000627:therapeutic use*; D002188:Cannabis; D000075202:Contraindications; D013759:Dronabinol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D009103:Multiple Sclerosis / Q000188:drug therapy; D009128:Muscle Spasticity / Q000188:drug therapy; D009325:Nausea / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D010936:Plant Extracts / Q000008:administration & dosage; D014839:Vomiting / Q000188:drug therapy
chemical_list: D002186:Cannabinoids; D004338:Drug Combinations; D010936:Plant Extracts; D002185:Cannabidiol; C011941:nabilone; D013759:Dronabinol; C587251:nabiximols